IASLC Announces that JTO Clinical and Research Reports Articles are Now Available on PubMed

IASLC Announces that JTO Clinical and Research Reports Articles are Now Available on PubMed

Press Release
Oct 12, 2021

Chris Martin, IASLC Media Relations | [email protected]

DENVER – October 12, 2021--Articles published in the JTO Clinical and Research Reports (JTO CRR) are now indexed and available through PubMed Central (PMC). PMC is a free archive of biomedical and life sciences journal literature at the United States National Institutes of Health’s National Library of Medicine (NIH/NLM). Since its founding in 2000, PMC has acted as a resource for quality scholarship from around the world. Currently, it hosts an archive of millions of articles which come from thousands of journals.

JTO Clinical and Research Reports articles are available at https://www.ncbi.nlm.nih.gov/pmc/journals/4097/.

In fewer than two years, JTO CRR expanded from a quarterly to monthly publication, and it adopted an article-based publishing model to promptly publish cutting-edge research. As an open-access journal, articles are immediately and permanently free to access by everyone.

“In this current environment, it is phenomenal that JTO CRR went from its first article published in January 2020 to PubMed indexing by September 2021,” said Alex A. Adjei, MD, PhD, Editor-in-Chief.

 JTO Clinical and Research Reports is the official open-access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors an open-access publication option and publishing the following article types in particular:

  • Phase I trials
  • Well-performed, single-arm phase II trials
  • Subset analyses of published trials
  • Impactful retrospective Studies
  • Database analysis
  • Large institutional series
  • High-quality case reports
  • Region-specific clinical trials
  • Subspecialty thoracic oncology studies
  • Selected high-quality meeting reports

 “This success is testament to the dedication and expertise of our editorial staff, the support of the IASLC board and staff, the guidance and oversight of our publisher, and the strong contributions of our Editorial Board, authors, and reviewers. It is a joy and privilege to work with this talented team,” said Dr. Adjei.

The International Association for the Study of Lung Cancer (IASLC) reported earlier this year that its main cancer journal, the Journal of Thoracic Oncology (JTO), improved its Impact Factor from 13.357 in 2019 to 15.609 in 2020.  The JTO, the official journal of the IASLC, now ranks 13th out of all 242 oncology journals and 4th out of all 64 respiratory system journals.

Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the Impact Factor for 2020 is the number of times articles published in 2018 and 2019 are cited in 2020.  The higher the Impact Factor, the more highly ranked the journal.  Journal citation reports are issued by Clarivate Analytics.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the JTO
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

Share